Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson director reports deferred share unit award
A Johnson & Johnson (JNJ) director reported receiving 247.378 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. After this transaction, the director beneficially owned 14,153.1187 DSUs in total.
The DSUs represent the fair market value of one share of Johnson & Johnson common stock and are to be settled in cash when the director’s service on the board ends. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend, keeping the director’s deferred compensation aligned with shareholder payouts.
Johnson & Johnson director Daniel E. Pinto reported a compensation-related equity transaction. On 12/09/2025, he acquired 154.611 Deferred Share Units (DSUs) under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors at a derivative security price of $202.12. Following this transaction, he beneficially owned 331.233 DSUs.
The DSUs represent deferred cash retainers and are to be settled in cash when his service as a director ends. Each DSU is tied to the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The reported balance also includes dividend equivalent rights accrued on DSUs he already held.
Johnson & Johnson director John Morikis reported buying company stock. On 11/26/2025, he acquired 1,250 shares of common stock at a price of $206.15 per share, coded as transaction type "P." After this purchase, he beneficially owned 1,848.51 shares, held directly. The Form 4 indicates the filing relates to one reporting person and shows no derivative securities transactions.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 13F reporting institutional holdings on behalf of its investment manager. The report lists 20 holdings with a total reported market value of $503,699,862. The filing names Johnson & Johnson Innovation - JJDC, Inc. as an included manager and is signed on 11-13-2025.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX) common stock by its subsidiary, Johnson & Johnson Innovation – JJDC, Inc. The filing lists sales of 52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
Johnson & Johnson reported significantly stronger results for the quarter and first nine months of 2025. Quarterly sales rose to $23.99 billion, up 6.8% from a year ago, with net earnings climbing to $5.15 billion versus $2.69 billion. Diluted EPS increased to $2.12 from $1.11.
For the first nine months, sales reached $69.63 billion, up 5.0%, while net earnings more than doubled to $21.69 billion, and diluted EPS rose to $8.94 from $4.38. Results benefited from a roughly $7 billion reversal of previously accrued talc reserves, partly offset by a higher effective tax rate of 21.5% following U.S. tax law changes.
The company closed the $14.5 billion acquisition of Intra-Cellular Therapies, adding CAPLYTA and a CNS pipeline to the Innovative Medicine segment. MedTech growth was supported by prior acquisitions such as Shockwave. As of October 17, 2025, there were 2,409,295,102 common shares outstanding.
Johnson & Johnson (JNJ) insider trade: EVP, Innovative Medicine, R&D, John C. Reed exercised 21,721 employee stock options at $157.92 per share and sold 21,721 common shares at a weighted average price of $192.7072 on 10/17/2025. Following these transactions, he directly beneficially owned 10,658 common shares and held 43,442 derivative securities (options). The sale price reflects multiple trades between $192.69 and $192.87.
Johnson & Johnson (JNJ) filed a Form 144 notice covering a proposed sale of 21,721 shares of common stock with an aggregate market value of $4,185,794.26. The filing lists an approximate sale date of 10/17/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities were acquired on 10/17/2025 via an option granted on 02/15/2024, with payment made on 10/17/2025 in cash. The notice states 2,408,338,872 shares outstanding. Over the past three months, John C. Reed sold 19,137 shares on 07/17/2025 for gross proceeds of $3,129,830.51.
Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.
The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.